Industry may benefit from planned boost to Taiwan health spending
This article was originally published in Scrip
Taiwan may increase its healthcare spending by as much as NT$130 billion ($4.34 billion) annually if a new top-level proposal makes it through to political approval, in a move designed in part to drive the development of the local pharma and biotech industries.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.